?

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Date: February 27, 2015
Pages: 323
Price:
US$ 10,995.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P1CC82CCFA3EN
Leaflet:

Download PDF Leaflet

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

SUMMARY

The lupus therapeutics market is dominated by generics and GlaxoSmithKline’s Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years. Following Benlysta’s launch, patients’ uptake has remained low, but due to its associated high price-tag Benlysta has managed to grow the lupus market in terms of value and is currently the top-selling drug in this market, having generated approximately $265.6m in 2014 in the seven major markets. There is high R&D activity for the development of new therapies for lupus and seven promising biological therapies have the potential to enter the SLE and LN market during the 2012-2022 forecast period. The introduction of new biologic drugs will shape the future competitive landscape and drive growth in the SLE and LN markets.

HIGHLIGHTS

KEY QUESTIONS ANSWERED
  • What was the impact of Benlysta on the lupus therapeutics market following its approval in 2011 and what is its future outlook in this market?
  • What do physicians think about Rituxan following its unsuccessful Phase III trials in LN, and how will it be used off-label in lupus during the forecast period?
  • What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in SLE and LN?
  • What are the significant unmet needs in the SLE and LN markets?
  • What are the remaining opportunities in the SLE and LN markets?
KEY FINDINGS
  • The key drivers of growth for the SLE and LN markets are the increasing uptake of GlaxoSmithKline’s Benlysta, the potential launch of new biologic drugs and the increasing number of prevalent cases of SLE and LN during the 2012-2022 forecast period.
  • R&D strategies include the development of me-too and first-in-class therapies, partnerships and acquisitions, and the development of products for LN.
  • The lupus therapeutics market is characterized by significant unmet needs. The most pressing unmet need is the development of new therapies that will offer potent clinical benefits, have a positive safety profile and increase the available treatment options for patients.
SCOPE
  • Overview of SLE and LN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Annualized SLE and LN therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the SLE and LN therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
  • Analysis of the current and future market competition in the global SLE and LN therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
REASONS TO BUY
  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global SLE and LN therapeutics markets.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SLE and LN therapeutics markets in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global SLE and LN therapeutics markets from 2012-2022.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 DISEASE OVERVIEW

3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology
3.2 Prognosis
3.3 Quality of Life
3.4 Symptoms

4 EPIDEMIOLOGY

4.1 Risk Factors and Comorbidities
  4.1.1 Women are at a higher risk of developing SLE than men
  4.1.2 Caucasians are at lower risk of developing SLE than other ethnicities
  4.1.3 Familial history has been associated with an increased risk of developing SLE
  4.1.4 Certain occupational and environmental exposures trigger SLE
4.2 Global Trends
  4.2.1 US
  4.2.2 5EU
  4.2.3 Japan
4.3 Forecast Methodology
4.4 Sources Used
  4.4.1 US
  4.4.2 France
  4.4.3 Germany
  4.4.4 Italy
  4.4.5 Spain
  4.4.6 UK
  4.4.7 Japan
4.5 Sources Not Used
  4.5.1 US
  4.5.2 5EU
  4.5.3 Japan
4.6 Forecast Assumptions and Methods
  4.6.1 US
  4.6.2 5EU
  4.6.3 Japan
4.7 Epidemiological Forecast of SLE (2012-2022)
  4.7.1 Diagnosed Prevalent Cases of SLE
  4.7.2 Age-Specific Prevalent Cases of SLE
  4.7.3 Sex-Specific Prevalent Cases of Diagnosed SLE
  4.7.4 Age-Standardized Prevalence of SLE
  4.7.5 Diagnosed Prevalent Cases of LN
  4.7.6 Prevalent Cases of LN, Segmented by Class
4.8 Discussion
  4.8.1 Conclusions on Epidemiology Trends
  4.8.2 Limitations of the Analysis
  4.8.3 Strengths of the Analysis

5 DISEASE MANAGEMENT

5.1 Diagnosis Overview
  5.1.1 SLE Diagnosis
  5.1.2 LN Diagnosis
5.2 Treatment Overview
5.3 US
  5.3.1 Diagnosis
  5.3.2 Clinical Practice
5.4 France
  5.4.1 Diagnosis
  5.4.2 Clinical Practice
5.5 Germany
  5.5.1 Diagnosis
  5.5.2 Clinical Practice
5.6 Italy
  5.6.1 Diagnosis
  5.6.2 Clinical Practice
5.7 Spain
  5.7.1 Diagnosis
  5.7.2 Clinical Practice
5.8 UK
  5.8.1 Diagnosis
  5.8.2 Clinical Practice
5.9 Japan
  5.9.1 Diagnosis
  5.9.2 Clinical Practice

6 COMPETITIVE ASSESSMENT

6.1 Overview
6.2 Strategic Competitor Assessment
6.3 Product Profiles - Major Brands
  6.3.1 Antimalarial Therapy (numerous brand names)
  6.3.2 Steroids (numerous brand names)
  6.3.3 Methotrexate (numerous brand names)
  6.3.4 Mycophenolate Mofetil (numerous brand names)
  6.3.5 Cyclophosphamide (numerous brand names)
  6.3.6 Azathioprine (numerous brand names)
  6.3.7 Calcineurin Inhibitors (numerous brand names)
  6.3.8 Benlysta (belimumab)
  6.3.9 Rituxan (rituximab)
  6.3.10 Minor Therapeutic Classes

7 OPPORTUNITY AND UNMET NEED

7.1 Overview
7.2 Unmet Needs
  7.2.1 Efficacious Treatments with Reduced Side Effects
  7.2.2 Management of LN
  7.2.3 Improvement in Patients’ Mortality
  7.2.4 Management of Lupus Comorbidities
  7.2.5 Sensitive and Reliable Biomarkers
  7.2.6 Physicians’ Education and Public Awareness of SLE
  7.2.7 Unmet Needs Gap Analysis
7.3 Opportunities
  7.3.1 Efficacious and Safe Therapies
  7.3.2 Therapies Targeting LN Patients
  7.3.3 Treatments for Common Lupus Comorbidities
  7.3.4 Discovery of Biomarkers

8 PIPELINE ASSESSMENT

8.1 Overview
8.2 Clinical Trial Mapping
  8.2.1 Clinical Trials by Therapy Type
8.3 Promising Drugs in Clinical Development
  8.3.1 Blisibimod (A-623)
  8.3.2 Atacicept
  8.3.3 Epratuzumab
  8.3.4 Lupuzor (rigerimod)
  8.3.5 Orencia (abatacept)
  8.3.6 Sifalimumab (MEDI-545)
  8.3.7 PF-04236921
  8.3.8 Anifrolumab (MEDI-546)
  8.3.9 Lulizumab Pegol (BMS-931699)
  8.3.10 BIIB023
  8.3.11 Voclosporin
8.4 Other Drugs in Development

9 CURRENT AND FUTURE PLAYERS

9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
  9.3.1 GlaxoSmithKline
  9.3.2 Roche
  9.3.3 UCB
  9.3.4 Bristol-Myers Squibb
  9.3.5 Anthera
  9.3.6 ImmuPharma
  9.3.7 Merck Serono
  9.3.8 AstraZeneca
  9.3.9 Pfizer

10 MARKET OUTLOOK

10.1 Global Markets
  10.1.1 Forecast
  10.1.2 Drivers and Barriers - Global Issues
10.2 US
  10.2.1 Forecast
  10.2.2 Key Events
  10.2.3 Drivers and Barriers
10.3 France
  10.3.1 Forecast
  10.3.2 Key Events
  10.3.3 Drivers and Barriers
10.4 Germany
  10.4.1 Forecast
  10.4.2 Key Events
  10.4.3 Drivers and Barriers
10.5 Italy
  10.5.1 Forecast
  10.5.2 Key Events
  10.5.3 Drivers and Barriers
10.6 Spain
  10.6.1 Forecast
  10.6.2 Key Events
  10.6.3 Drivers and Barriers
10.7 UK
  10.7.1 Forecast
  10.7.2 Key Events
  10.7.3 Drivers and Barriers
10.8 Japan
  10.8.1 Forecast
  10.8.2 Key Events
  10.8.3 Drivers and Barriers

11 APPENDIX

11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
  11.4.1 Diagnosed SLE and LN Patients
  11.4.2 Percent Drug-Treated Patients
  11.4.3 Drugs Included in Each Therapeutic Class
  11.4.4 Launch and Patent Expiry Dates
  11.4.5 General Pricing Assumptions
  11.4.6 Individual Drug Assumptions
  11.4.7 Generic Erosion
  11.4.8 Pricing of Pipeline Agents
11.5 Physicians and Specialists Included in this Study
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
  11.7.1 Analysts
  11.7.2 Epidemiologist
  11.7.3 Global Head of Healthcare
11.8 About GlobalData
11.9 Disclaimer

LIST OF FIGURES

Figure 1: Overview of the Etiology and Pathogenesis of SLE
Figure 2: Overview of the BAFF/APRIL Ligand and Receptor System
Figure 3: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, 2012-2022
Figure 4: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012
Figure 5: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, 2012
Figure 6: 7MM, Age-Standardized Prevalence (%) of Diagnosed SLE, All Ages, by Sex, 2012
Figure 7: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, 2012-2022
Figure 8: 6MM, Prevalent Cases of LN, by Class, All Ages, Both Sexes, 2012
Figure 9: Overview of the Treatment Management of SLE
Figure 10: SLE and LN Therapeutics - Clinical Trials by Type of Therapy and Development Stage, January 2015
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in SLE and LN, 2012-2022
Figure 12: Company Portfolio Gap Analysis in SLE and LN, 2012-2022
Figure 13: Global Sales for SLE and LN by Region, 2012-2022
Figure 14: Sales for SLE in the Seven Major Markets by Drug Class According to Market Value and Volume, 2012-2022
Figure 15: Sales for LN in the Seven Major Markets by Drug Class According to Market Value and Volume, 2012-2022
Figure 16: Sales for SLE and LN in the US by Drug Class, 2012-2022
Figure 17: Sales for SLE and LN in France by Drug Class, 2012-2022
Figure 18: Sales for SLE and LN in Germany by Drug Class, 2012-2022
Figure 19: Sales for SLE and LN in Italy by Drug Class, 2012-2022
Figure 20: Sales for SLE and LN in Spain by Drug Class, 2012-2022
Figure 21: Sales for SLE and LN in the UK by Drug Class, 2012-2022
Figure 22: Sales for SLE and LN in Japan by Drug Class, 2012-2022

COMPANIES MENTIONED

GlaxoSmithKline
Roche
UCB
Bristol-Myers Squibb
Anthera
ImmuPharma
Merck Serono
AstraZeneca
Pfizer

GlobalData foresees that seven products could potentially enter the lupus market during the 2012-2022 forecast period. The launch of new biologic drugs will increase treatment options, improve treatment management, and drive growth in the SLE and LN markets. Although the need for safe and effective new treatments is paramount for patients with lupus, products in the pipeline are expected to face many challenges in gaining patient share following their entry into the lupus market.

New entrants will be required to demonstrate their clinical benefits to gain physicians' and patients' confidence for their use, overcome reimbursement challenges, and will face increasing competition from competing biologic products and inexpensive, potent immunosuppressive and steroid therapies.

The development of new drugs that are more efficacious and safer than currently available treatments remains the most pressing unmet need for the management of patients with SLE and LN.

With the purchase of a site or global license of GlobalData's report "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event Driven Update", you will receive an interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy, and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

The material was prepared in May, 2015.

LIST OF TABLES

Table 1: Symptoms of SLE
Table 2: Risk Factors Associated with SLE
Table 3: World Health Organization Morphologic Classification of Lupus Nephritis (Modified in 1982)
Table 4: Sources of Prevalence Data Used in this Analysis
Table 5: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, Select Years 2012-2022
Table 6: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012
Table 7: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, by Sex, N, Row (%), 2012
Table 8: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, Select Years 2012-2022
Table 9: 6MM, Prevalent Cases in the Different Classes of LN, All Age, Both Sexes, N, Row (%), 2012
Table 10: 1997 Updated ACR Criteria for Classification of SLE
Table 11: The SLICC Clinical and Immunologic Criteria for Classification of SLE
Table 12: WHO and ISN/RPS classifications of LN
Table 13: Treatment Guidelines for SLE and LN
Table 14: Most Prescribed Drugs for SLE and LN by Class in the Global Markets
Table 15: Leading Treatments for SLE and LN, 2015
Table 16: Product Profile - Hydroxychloroquine
Table 17: Antimalarial Therapy SWOT Analysis, 2015
Table 18: Global SLE Sales Forecasts ($m) for Antimalarial Therapy, 2012-2022
Table 19: Global LN Sales Forecasts ($m) for Antimalarial Therapy, 2012-2022
Table 20: Product Profile - Steroids
Table 21: Steroids SWOT Analysis, 2015
Table 22: Global SLE Sales Forecasts ($m) for Steroid Therapy, 2012-2022
Table 23: Global LN Sales Forecasts ($m) for Steroid Therapy, 2012-2022
Table 24: Product Profile - Methotrexate
Table 25: Methotrexate SWOT Analysis, 2015
Table 26: Global SLE Sales Forecasts ($m) for MTX, 2012-2022
Table 27: Global LN Sales Forecasts ($m) for MTX, 2012-2022
Table 28: Product Profile - Mycophenolate Mofetil
Table 29: Mycophenolate Mofetil SWOT Analysis, 2015
Table 30: Global SLE Sales Forecasts ($m) for MMF, 2012-2022
Table 31: Global LN Sales Forecasts ($m) for MMF, 2012-2022
Table 32: Product Profile - Cyclophosphamide
Table 33: Cyclophosphamide SWOT Analysis, 2015
Table 34: Global SLE Sales Forecasts ($m) for CYC, 2012-2022
Table 35: Global LN Sales Forecasts ($m) for CYC, 2012-2022
Table 36: Product Profile - Azathioprine
Table 37: Azathioprine SWOT Analysis, 2015
Table 38: Global SLE Sales Forecasts ($m) for AZA, 2012-2022
Table 39: Global LN Sales Forecasts ($m) for AZA, 2012-2022
Table 40: Product Profile - Calcineurin Inhibitors
Table 41: Calcineurin Inhibitors SWOT Analysis, 2015
Table 42: Global SLE Sales Forecasts ($m) for Calcineurin Inhibitors, 2012-2022
Table 43: Global LN Sales Forecasts ($m) for Calcineurin Inhibitors, 2012-2022
Table 44: Product Profile - Benlysta
Table 45: Benlysta SWOT Analysis, 2015
Table 46: Global SLE Sales Forecasts ($m) for Benlysta, 2012-2022
Table 47: Global LN Sales Forecasts ($m) for Benlysta, 2012-2022
Table 48: Product Profile - Rituxan
Table 49: Rituxan SWOT Analysis, 2015
Table 50: Global SLE Sales Forecasts ($m) for Rituxan, 2012-2022
Table 51: Global LN Sales Forecasts ($m) for Rituxan, 2012-2022
Table 52: Summary of Minor Therapeutic Classes in SLE and LN, 2015
Table 53: Overall Unmet Needs in SLE and LN - Current Level of Attainment
Table 54: Clinical Unmet Needs in SLE and LN - Gap Analysis, 2015
Table 55: Drugs in Late-Stage Clinical Development for SLE and LN, 2015
Table 56: Product Profile - Blisibimod
Table 57: Blisibimod SWOT Analysis, 2015
Table 58: Global SLE Sales Forecasts ($m) for Blisibimod, 2012-2022
Table 59: Global LN Sales Forecasts ($m) for Blisibimod, 2012-2022
Table 60: Product Profile - Atacicept
Table 61: Atacicept SWOT Analysis, 2015
Table 62: Global SLE Sales Forecasts ($m) for Atacicept, 2012-2022
Table 63: Global LN Sales Forecasts ($m) for Atacicept, 2012-2022
Table 64: Product Profile - Epratuzumab
Table 65: Epratuzumab SWOT Analysis, 2015
Table 66: Global SLE Sales Forecasts ($m) for Epratuzumab, 2012-2022
Table 67: Global LN Sales Forecasts ($m) for Epratuzumab, 2012-2022
Table 68: Product Profile - Lupuzor
Table 69: Lupuzor SWOT Analysis, 2015
Table 70: Global SLE Sales Forecasts ($m) for Lupuzor, 2012-2022
Table 71: Global LN Sales Forecasts ($m) for Lupuzor, 2012-2022
Table 72: Product Profile - Orencia
Table 73: Orencia SWOT Analysis, 2015
Table 74: Global SLE Sales Forecasts ($m) for Orencia, 2012-2022
Table 75: Global LN Sales Forecasts ($m) for Orencia, 2012-2022
Table 76: Product Profile - Sifalimumab
Table 77: Sifalimumab SWOT Analysis, 2015
Table 78: Global SLE Sales Forecasts ($m) for Sifalimumab, 2012-2022
Table 79: Global LN Sales Forecasts ($m) for Sifalimumab, 2012-2022
Table 80: Product Profile - PF-04236921
Table 81: PF-04236921 SWOT Analysis, 2015
Table 82: Global SLE Sales Forecasts ($m) for PF-04236921, 2012-2022
Table 83: Global LN Sales Forecasts ($m) for PF-04236921, 2012-2022
Table 84: Product Profile - Anifrolumab
Table 85: Anifrolumab SWOT Analysis, 2015
Table 86: Product Profile - Lulizumab Pegol
Table 87: Lulizumab Pegol SWOT Analysis, 2015
Table 88: Product Profile - BIIB023
Table 89: BIIB023 SWOT Analysis, 2015
Table 90: Product Profile - Voclosporin
Table 91: Voclosporin SWOT Analysis, 2015
Table 92: Drugs in Early-stage Clinical Development for SLE and LN, 2015
Table 93: Key Companies in the SLE and LN Market, 2015
Table 94: GSK’s SLE and LN Portfolio Assessment, 2015
Table 95: GlaxoSmithKline SWOT Analysis, 2015
Table 96: Roche’s SLE and LN Portfolio Assessment, 2015
Table 97: Roche SWOT Analysis, 2015
Table 98: UCB’s SLE and LN Portfolio Assessment, 2015
Table 99: UCB SWOT Analysis, 2015
Table 100: BMS’s SLE and LN Portfolio Assessment, 2015
Table 101: BMS SWOT Analysis, 2015
Table 102: Anthera’s SLE and LN Portfolio Assessment, 2015
Table 103: Anthera SWOT Analysis, 2015
Table 104: ImmuPharma’s SLE and LN Portfolio Assessment, 2015
Table 105: ImmuPharma SWOT Analysis, 2015
Table 106: Merck Serono’s SLE and LN Portfolio Assessment, 2015
Table 107: Merck Serono SWOT Analysis, 2015
Table 108: AstraZeneca’s SLE and LN Portfolio Assessment, 2015
Table 109: AstraZeneca SWOT Analysis, 2015
Table 110: Pfizer’s SLE and LN Portfolio Assessment, 2015
Table 111: Pfizer SWOT Analysis, 2015
Table 112: Global Sales Forecasts ($m) for SLE, 2012-2022
Table 113: Global Sales Forecasts ($m) for LN, 2012-2022
Table 114: SLE and LN Market - Global Drivers and Barriers, 2012-2022
Table 115: Sales Forecasts ($m) for SLE in the US, 2012-2022
Table 116: Sales Forecasts ($m) for LN in the US, 2012-2022
Table 117: Key Events Impacting Sales for SLE and LN in the US, 2012-2022
Table 118: SLE and LN Market in the US - Drivers and Barriers, 2012-2022
Table 119: Sales Forecasts ($m) for SLE in France, 2012-2022
Table 120: Sales Forecasts ($m) for LN in France, 2012-2022
Table 121: Key Events Impacting Sales for SLE and LN in France, 2012-2022
Table 122: SLE and LN Market in France - Drivers and Barriers, 2012-2022
Table 123: Sales Forecasts ($m) for SLE in Germany, 2012-2022
Table 124: Sales Forecasts ($m) for LN in Germany, 2012-2022
Table 125: Key Events Impacting Sales for SLE and LN in Germany, 2012-2022
Table 126: SLE and LN Market in Germany - Drivers and Barriers, 2012-2022
Table 127: Sales Forecasts ($m) for SLE in Italy, 2012-2022
Table 128: Sales Forecasts ($m) for LN in Italy, 2012-2022
Table 129: Key Events Impacting Sales for SLE and LN in Italy, 2012-2022
Table 130: SLE and LN Market in Italy - Drivers and Barriers, 2012-2022
Table 131: Sales Forecasts ($m) for SLE in Spain, 2012-2022
Table 132: Sales Forecasts ($m) for LN in Spain, 2012-2022
Table 133: Key Events Impacting Sales for SLE and LN in Spain, 2012-2022
Table 134: SLE and LN Market in Spain - Drivers and Barriers, 2012-2022
Table 135: Sales Forecasts ($m) for SLE in the UK, 2012-2022
Table 136: Sales Forecasts ($m) for LN in the UK, 2012-2022
Table 137: Key Events Impacting Sales for SLE and LN in the UK, 2012-2022
Table 138: SLE and LN Market in the UK - Drivers and Barriers, 2012-2022
Table 139: Sales Forecasts ($m) for SLE in Japan, 2012-2022
Table 140: Sales Forecasts ($m) for LN in Japan, 2012-2022
Table 141: Key Events Impacting Sales for SLE and LN in Japan, 2012-2022
Table 142: SLE and LN Market in Japan - Drivers and Barriers, 2012-2022
Table 143: Key Launch Dates
Table 144: Key Patent Expiries
Table 145: Number of Physicians Surveyed by Country

Skip to top


Ask Your Question

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: